2026年1月19日 华宝基金管理有限公司 为促进华宝中证金融科技主题交易型开放式指数证券投资基金（基金简称：金融科技ETF，基金代码： 159851）的市场流动性和平稳运行，根据《深圳证券交易所证券投资基金业务指引第2号一一流动性服 务（2023年修订）》等相关规定，我司自2026年1月19日起新增国泰海通证券股份有限公司为金融科技 ETF的流动性服务商。 特此公告。 ...

国泰海通证券股份有限公司 二○二六年一月十七日 为进一步优化网点布局，国泰海通证券股份有限公司（以下简称"公司"）决定撤销深圳深南大道证券营 业部，根据新修订的《中华人民共和国证券法》和《关于取消或调整证券公司部分行政审批项目等事项 的公告》（证监会公告（2020）018）相关要求，公司将妥善处理深圳深南大道证券营业部客户资产， 结清深圳深南大道证券营业部证券业务并终止营业活动，办理工商注销等相关手续，并向上述营业部所 在地中国证监会派出机构备案。 特此公告。 ...

Group 1 - The stock price of Youche Technology (688479.SH) fell by 10.66% to 22.87 yuan as of the market close [1] - Youche Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 11, 2023, with an initial opening price of 31.00 yuan, closing at 29.19 yuan, reflecting a decline of 14.12% on the first day [1] - The company is currently in a state of stock price decline, having broken its initial offering price [1] Group 2 - Youche Technology issued a total of 36,079,400 shares at an offering price of 33.99 yuan per share, with no existing shares being transferred [1] - The total amount raised from the initial public offering (IPO) was 1.226 billion yuan, with a net amount of 1.085 billion yuan after deducting issuance costs, exceeding the original plan by 522.29 million yuan [1] - The funds raised are intended for projects including upgrades to the automotive marketing system, owner service platform, and data analysis platform [1] Group 3 - The strategic placement of shares was composed of investments from subsidiaries of the underwriter, with Zhenyu Investment, a wholly-owned alternative investment subsidiary of Guotai Junan, participating [2] - Zhenyu Investment acquired 1,443,176 shares, amounting to approximately 49.05 million yuan, which represents 4.00% of the total issuance [2]

Core Viewpoint - The company, Huaxiang Co., Ltd. (603112.SH), announced a significant change in the equity holdings of its controlling shareholder, Huaxiang Industrial Co., Ltd., which reduced its stake from 55.00% to 53.01% through a share reduction of 10,722,374 shares, amounting to approximately 210 million yuan [1] Group 1: Shareholder Equity Changes - Huaxiang Industrial reduced its holdings between January 14 and January 15, 2026, impacting the company's ownership structure [1] - The weighted average price of Huaxiang shares during this period was 19.564 yuan [1] - The reduction in shareholding triggered a notification as it crossed the 1% threshold [1] Group 2: Fundraising Activities - Huaxiang Co., Ltd. was listed on the Shanghai Stock Exchange on September 17, 2020, with an initial public offering price of 7.82 yuan per share, raising a total of 416 million yuan [1] - The company faced a shortfall of approximately 49.85 million yuan compared to its planned fundraising target of 466 million yuan [1] - The total issuance costs for the company amounted to 51.5142 million yuan, with underwriting and sponsorship fees of 33.0189 million yuan [2] Group 3: Recent Financing Initiatives - The company issued 26,649,746 shares at an issue price of 7.88 yuan, raising a total of 210 million yuan, with net proceeds of approximately 207.42 million yuan after deducting fees [3] - A proposed issuance of convertible bonds aims to raise up to 1.30752 billion yuan, intended for enhancing core component capacity, extending the industrial chain, and supplementing working capital [3]

Core Viewpoint - Guotai Junan Securities has experienced a decline in stock price and significant changes in trading activity, indicating potential volatility in the market [1][2]. Group 1: Stock Performance - As of January 15, Guotai Junan's stock price decreased by 2.02%, trading at 20.34 CNY per share with a total transaction volume of 1.753 billion CNY [1]. - Year-to-date, the stock has dropped by 1.02%, with a 4.60% decline over the last five trading days, a 0.30% increase over the last 20 days, and a 9.35% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Guotai Junan reported a revenue of 45.892 billion CNY, reflecting a year-on-year growth of 58.24%, and a net profit attributable to shareholders of 22.074 billion CNY, up 131.80% year-on-year [2]. - The company has distributed a total of 45.263 billion CNY in dividends since its A-share listing, with 17.148 billion CNY distributed over the past three years [3]. Group 3: Shareholder and Ownership Structure - As of September 30, 2025, the number of shareholders decreased to 359,400, a reduction of 4.60%, while the average number of circulating shares per person increased by 4.82% to 37,577 shares [2]. - Among the top ten circulating shareholders, China Securities Finance Corporation holds 421 million shares, remaining unchanged, while Guotai Zhongzheng CSI Securities Company ETF is a new entrant with 292 million shares [3].

经济观察网证监会网站显示，北京天圣华信息技术股份有限公司2026年1月14日向北京证监局办理辅导 备案登记，辅导机构为国泰海通证券股份有限公司。 ...

公告显示，安阳启旭、河南翔宇健康产业管理有限公司同受公司实际控制人何永正、郭军玲夫妇控 制。 翔宇医疗于2021年3月31日在上交所科创板上市，发行数量为40,000,000股（全部为新股，不安排老 股转让），发行价格为28.82元/股，保荐机构为海通证券股份有限公司（现更名为国泰海通证券股份有 限公司），保荐代表人为刘君、岑平一。 翔宇医疗首次公开发行募集资金总额115,280.00万元；扣除发行费用后，募集资金净额为104,965.66 万元。翔宇医疗最终募集资金净额较原计划多34,165.66万元。翔宇医疗于2021年3月25日发布的招股说 明书显示，公司拟募集资金70,800.00万元，智能康复医疗设备生产技术改造项目、养老及产后康复医疗 设备生产建设项目、康复设备研发及展览中心建设项目、智能康复设备（西南）研销中心项目、运营储 备资金。 翔宇医疗发行费用总额10,314.34万元，其中保荐及承销费用7,939.04万元。 中国经济网北京1月14日讯 翔宇医疗(688626.SH)昨日晚间披露关于股东减持股份计划公告。 公司股东安阳启旭贸易咨询服务中心（有限合伙）（简称"安阳启旭"）持有公司股份 8, ...

证券代码：603376 证券简称：大明电子 公告编号：2026-001 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意大明电子股份有限公司首次公开发行股票注册的批复》（证监许 可〔2025〕1643号）同意注册，并经上海证券交易所同意，大明电子股份有限公司（以下简称"公司"） 向社会公开发行人民币普通股（A股）4,000.10万股，发行价格为12.55元/股，本次发行募集资金总额为 502,012,550.00元，扣除发行费用78,190,571.41元（不含增值税）后，募集资金净额为423,821,978.59 元。容诚会计师事务所（特殊普通合伙）对公司本次公开发行新股的资金到位情况进行了审验并出具了 《验资报告》（容诚验字[2025]230Z0132号）。 二、募集资金管理情况 为了规范公司募集资金的存放、使用和管理，维护投资者的合法权益，确保公司募投项目顺利开展，提 高募集资金使用效率，根据《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指引第 1号 ...

Core Viewpoint - Guotai Junan Securities has shown a mixed performance in stock price, with a year-to-date increase of 5.11% but a recent decline of 2.79% over the last five trading days [2]. Financial Performance - For the period from January to September 2025, Guotai Junan achieved a revenue of 45.892 billion yuan, representing a year-on-year growth of 58.24%. The net profit attributable to shareholders was 22.074 billion yuan, marking a significant increase of 131.80% [2]. - Cumulative cash dividends since the A-share listing amount to 45.263 billion yuan, with 17.148 billion yuan distributed over the last three years [3]. Stock and Market Activity - As of January 14, the stock price of Guotai Junan was 21.60 yuan per share, with a trading volume of 5.01 billion yuan and a market capitalization of 380.785 billion yuan [1]. - The stock has a turnover rate of 0.17%, with net inflows of main funds amounting to 6.5526 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 359,400, a decrease of 4.60% from the previous period. The average circulating shares per person increased by 4.82% to 37,577 shares [2]. - The top ten circulating shareholders include China Securities Finance Corporation, holding 421 million shares, and Guotai Zhongzheng CSI Securities Company ETF, which is a new entrant holding 292 million shares [3].

Core Viewpoint - Tianjiao Biotechnology Co., Ltd. has completed its IPO counseling registration and is preparing for its listing on the New Third Board, with a structured four-phase approach to ensure compliance and governance [2][4]. Group 1: Company Overview - Tianjiao Biotechnology was established in December 2004, with a registered capital of 51.03 million yuan, located in Heze City, specializing in the research, production, and sales of food ingredients [4]. - The company has received multiple accolades, including being recognized as a national high-tech enterprise and a leading enterprise in Shandong Province's "Top Ten" industrial clusters [4]. - The controlling shareholder is Shandong Tianjiu Industrial Group Co., Ltd., which holds 82.39% of the shares, with the actual controllers indirectly controlling 84.35% of the company [4]. Group 2: Business Operations - Tianjiao Biotechnology focuses on functional powdered oils, solid beverages, and baking materials, with a strong emphasis on R&D [4]. - The company has established a multi-dimensional R&D framework, including six provincial-level R&D platforms and four major R&D centers across China, holding 77 patents, including 22 invention patents [4]. Group 3: Financial Aspects - The company faces risks related to raw material price fluctuations, with direct material costs constituting 84.81%, 83.50%, and 83.81% of the main business costs for 2023, 2024, and the first half of 2025, respectively [5]. - Due to rising product costs, the gross profit margin for the main business decreased to 22.46% in the first half of 2025 [5].